agonistas de glp 1 Fundación RedGDPS Agonistas del receptor GLP-1 |
Description
10.1007/s43032-023-01222-y Reprod Sci
Evidence suggests that favoring sustained G protein signaling over arrestin-driven internalization can prolong cyclic AMP production and insulin secretion, which has made biased agonism a deliberate goal in molecular design rather than an academic curiosity
Dupixent (dupilumab) Disease area(s): Immunology/respiratory Manufacturer(s): Sanofi/Regeneron 2024 Sales (USD): $14.15 billion Why it sold so well: Co-developed by Sanofi and Regeneron, Dupixent achieved significant success in 2024, with global net sales reaching $14.15 billion a 22% increase over 2023
01Clinically-Driven Founded and directed by cellular medicine experts
